Skip to main content

Table 5 a, Association between outcome (Relapse vs. NED) and dichotomized biomarkers at baseline. b, Association of baseline dichotomized biomarkers with irAE (Yes vs. No) for a total 55 patients

From: Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

Biomarker Outcome n (%) Odds Ratio Fisher
    (95% CI) p-value
a. Association between outcome (Relapse/NED) and dichotomized baseline biomarkers by median
%-Ki67 + EOMES + CD8+ (n = 39)    11.25 ( 2.52, 50.27) 0.0012
<=2.11 Relapse 15 ( 75.0)   
<=2.11 NED 5 ( 25.0)   
2.11 Relapse 4 ( 21.1)   
>2.11 NED 15 ( 78.9)   
%-EOMES + CD8+ (n = 54)    3.77 ( 1.16, 12.27) 0.0473
<=55.6 Relapse 14 ( 51.9)   
<=55.6 NED 13 ( 48.1)   
>55.6 Relapse 6 ( 22.2)   
>55.6 NED 21 ( 77.8)   
b. Association between irAE (Yes/No) and dichotomized baseline biomarkers by median
%-Ki67 + EOMES + CD4+ (n = 39)    8.00 ( 1.74, 36.70)  0.0079
<=0.446 Yes 12 ( 60.0)   
<=0.446 No 8 ( 40.0)   
>0.446 Yes 3 ( 15.8)   
>0.446 No 16 ( 84.2)   
  1. Ki67 and EOMES that was stained intracellularly in a total of 36 paired specimens of PBMC prior to and after four doses of ipilimumab was analyzed by flow cytometry.